Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals

Naoyuki Taira¹, Sakura Toguchi¹, Mio Miyagi¹, Tomoari Mori², Hiroaki Tomori³, Koichi Oshiro⁴, Osamu Tamai⁵, Mitsuo Kina⁶, Masatake Miyagi⁷, Kentaro Tamaki⁸, Mary K Collins⁹, and Hiroki Ishikawa¹

¹ Immune Signal Unit, Okinawa Institute of Science and Technology, Graduate University (OIST), Onna-son, Okinawa, Japan.

² Research Support Division, Occupational Health and Safety, OIST, Onna-son, Okinawa, Japan

³ Yaesu Clinic, Naha-city, Okinawa, Japan

⁴ Ohama Daiichi Hospital, Naha-city, Okinawa, Japan

⁵ Akebono Clinic, Naha-city, Okinawa, Japan

⁶ Kina Clinic, Naha-city, Okinawa, Japan

⁷ Arakawa Clinic, Naha-city, Okinawa, Japan

⁸ Naha-Nishi Clinic, Department of Breast Surgery, Naha-city, Okinawa, Japan

⁹ Research Support Division, Office of the Provost, OIST, Onna-son, Okinawa, Japan.

Corresponding author

Hiroki Ishikawa PhD

hiroki.ishikawa@oist.jp

Tel: 81-098-966-1601

Abstract

Pre-existing SARS-CoV-2-specific T cells, but not antibodies, have been detected in some unexposed individuals. This may account for some of the diversity in clinical outcomes ranging from asymptomatic infection to severe COVID-19. Although age is a risk factor for COVID-19, how age affects SARS-CoV-2-specific T cell responses remains unknown. We found that some pre-existing T cell responses to specific SARS-CoV-2 proteins, Spike (S) and Nucleoprotein (N), were significantly lower in elderly donors (>70 years old) who were seronegative for S than in young donors. However, substantial pre-existing T cell responses to the viral membrane (M) protein were detected in some elderly donors. These responses likely compensate for loss of T cell responses specific to S and N. In contrast, young and elderly donors exhibited comparable T cell responses to S, N, and M proteins after infection with SARS-CoV-2. M-specific responses were mediated by CD4 T cells producing interferon- γ in both seronegative and seropositive individuals. T cells in seronegative elderly donors responded to various M-derived peptides, while the response after SARS-CoV-2 infection was apparently focused on a single peptide. These data suggest that diversity of target antigen repertoire for pre-existing SARS-CoV-2-specific T cells declines with age, but the magnitude of pre-existing T cell responses is maintained by T cells reactive to specific viral proteins such as M. A better understanding of the role of pre-existing SARS-CoV-2-specific T cells that are less susceptible to age-related loss

may contribute to development of more effective vaccines for elderly people.

Introduction

There is extensive individual variation in severity of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from asymptomatic infection to fatal pneumonia (1). Various factors, including age, sex, and comorbidities such as obesity and diabetes, influence the risk of severe COVID-19 (2-4). For example, morbidity and mortality among the elderly are significantly higher than among the young (2). Consideration of protective measures for individuals vulnerable to COVID-19 should be particularly important to control the pandemic (5). However, the cellular and molecular bases of the variable risk of COVID-19 remain poorly understood.

T cells are assumed to mediate both protective and pathogenic immune responses to SARS-CoV-2 infection (6, 7). The magnitude and quality of T cell responses induced by SARS-CoV-2 infection are highly heterogeneous and are likely associated with COVID-19 clinical outcomes. For example, SARS-CoV-2-specific T cell numbers and their interferon- γ (IFN- γ) expression in severe COVID-19 patients are lower than in mild COVID-19 patients (8-10). Furthermore, asymptomatic COVID-19 patients tend to have

increased SARS-CoV-2-specific T cells expressing higher levels of IFN- γ compared to symptomatic patients (11). This individual variation in T cell responses may be partly explained by heterogeneity in levels of pre-existing SARS-CoV-2-reactive T cells.

Some individuals who have not been exposed to SARS-CoV-2 have nonetheless acquired SARS-CoV-2-reactive T cells, probably through exposure to other common cold coronaviruses (12-14). Pre-existing CD4 and CD8 memory T cells, specific to various SARS-CoV-2 proteins, including the structural proteins, Spike (S), Membrane (M), and Nucleoprotein (N), have been detected with significant individual variation (D. Wyllie et al., manuscript posted on medRxiv DOI: 10.1101/2020.11.02.20222778). These pre-existing SARS-CoV-2-reactive T cells are associated with immune protection against COVID-19; however, in other cases, they may exacerbate COVID-19 severity (15, 16). As many of the current vaccines express the SARS-CoV-2 S protein, only pre-existing S-reactive T cells are activated by these vaccines (Refs. 17 and L. Loyal et al., manuscript posted on medRxiv DOI: 10.1101/2021.04.01.21252379). Several studies have reported age-related differences in SARS-CoV-2-specific T cell responses in COVID-19 patients (Refs. 9 and C. A. Cohen et al., manuscript posted on medRxiv DOI: 10.1101/2021.02.02.21250988); however, the effect of age on pre-existing SARS-CoV-2-reactive T cells remains unknown.

In this study, we compared frequencies of T cells reactive to SARS-CoV-2 S, N, and M antigens between young and elderly donors. The relatively elderly Okinawan population, and the moderate rate of SARS-CoV-2 infection in Okinawa, allowed us to examine pre-existing SARS-CoV-2-specific T cells in a cohort of elderly (>70 years old) individuals. We found that pre-existing T cell responses to S and N antigens are significantly impaired in elderly donors compared to young donors, but a proportion of elderly donors exhibit significant, high levels of M-reactive T cell responses. These data provide new insights into age-related alteration of pre-existing SARS-CoV-2-specific T cells.

Methods

Subjects

The study design was approved by the Okinawa Institute of Science and Technology, Graduate University (OIST) human subjects ethics committee (applications HSR-2020-024, HSR-2020-028). All donors provided informed written consent. Young (20 to 50 years of age, n=66) and elderly volunteers (over 70 years of age, n=52) were recruited in Okinawa, Japan, between October, 2020 and April, 2021. 90 donors (48 young and 42 elderly) had no history of COVID-19, while 28 donors (18 young and 10 elderly) who recovered from COVID-19 had positive COVID-19 PCR test results 1-3 months before blood collection. Plasma from each donor was tested for SARS-CoV-2-specific antibodies using SARS-Cov-2 Antibody Detection Kits (KURABO RF-NC001, RF-NC002) or Cellex qSARS-Cov-2 IgG/IgM Cassette Rapid Tests (Cellex 5513C). Four (3 young and 1 elderly) of 90 donors who had no history of COVID-19 and 26 (16 young and 10 elderly) of 28 donors who had recovered from COVID-19 were seropositive for SARS-CoV-2 S antigen. Based on antibody test results, donors were grouped into seronegative young (n=45, 40 % male, 60% female; mean age 38 years, age range 23-49 years), seronegative elderly (n=41, 17 % male, 83% female; mean age 81 years, age range 70-93 years), seropositive young (n=19, 63 % male, 37% female; mean age 41 years, age range

20-50 years), and seropositive elderly (n=11, 45 % male, 55% female; mean age 78 years, age range 70-91 years).

Peripheral blood mononuclear cells (PBMCs) and plasma isolation.

Blood samples were collected in heparin-coated tubes (TERUMO; VP-H100K). PBMCs and plasma were separated using Leucosep tubes pre-filled with Ficoll-Paque Plus (Greiner; 163288). After adding 5 mL of blood and 3 mL of AIM-V medium (Thermo; 12055091), Leucosep tubes were centrifuged at 1,000 g at room temperature for 10 min. The white layer containing PBMCs was collected, washed with 10 mL AIM-V medium and centrifuged for 7 min at 600 g, followed by a second washing with centrifugation for 7 min at 400 g. PBMC pellets were resuspended in 500 µL CTL test medium (Cellular Technology Limited (CTL); CTLT-010). Fresh PBMCs were used for IFN-γ ELISpot assays. PBMCs used for flow cytometry analysis and epitope mapping analysis were stored with CTL-cryo ABC media (CTL; CTLC-ABC) in liquid nitrogen.

IFN-γ ELISpot assay

Peptide pools for SARS-CoV-2 S (JPT; PM-WCPV-S-1), N (Miltenyi;130-126-698), and M (Miltenyi;130-126-702) proteins dissolved in DMSO (500 µg/mL for S) or water (50

μg/mL for N and M) were used for cell stimulation. IFN-γ ELISpot assays were performed using Human IFN-γ Single-Color Enzymatic ELISpot kits (CTL; hIFNγp-2M), according to the manufacturer's instructions. Briefly, freshly isolated PBMCs (1-4 x 10⁵ cells per well) were stimulated with 1 μg/mL peptide solutions for each SARS-CoV-2 protein for 18-20 h. For each sample analysis, negative controls (cells treated with equimolar amounts of DMSO) and positive controls (cells treated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA) and 1 μg/mL ionomycin) were included. After incubation, plates were washed and developed with detection reagents included in the kits. Spots were counted using a CTL ImmunoSpot S6 Analyzer. Antigen-specific spot counts were determined by subtracting background spot counts in a negative control well from the wells treated with peptide pools. If >30 spots/10⁶ PBMCs in the negative control well or <30 spots/10⁶ PBMCs in the positive control well were detected, sample data were excluded from analysis.

Flow cytometry

Frozen PBMCs were thawed, washed with CTL wash supplement (CTL; CTL-W-010), and rested in CTL test medium overnight. Then, cells were resuspended in RPMI1640 (Gibco) medium supplemented with 5% (v/v) human AB-serum (PAN-Biotech; P30-

2901), seeded into 96-well, U-bottom culture plates (10^6 cells per well), and either left unstimulated (cells treated with equimolar amounts of DMSO) or stimulated with $1\mu\text{g/mL}$ SARS-CoV-2 M peptide pool for 7 h in the presence of $1\mu\text{g/mL}$ anti-CD40 (5C3; Biolegend; 334302) and $1\mu\text{g/mL}$ anti-CD28 antibodies (CD28.2; Biolegend; 302934). Brefeldin A ($1\mu\text{g/mL}$) (Biolegend; 420601) was added for the last 2 h. After stimulation, cells were incubated with anti-Fc receptor-blocking antibody (Biolegend; 422301) and NIR-Zombie (Biolegend; 423106) and stained with anti-CD3 (OKT3; Biolegend; 1:200), anti-CD4 (clone PPA-T4; Biolegend; 1:200), anti-CD8 (SK1; Biolegend; 1:200), anti-CD45RA (HI100; Biolegend; 1:100), and anti-CCR7 (G043H7; Biolegend; 1:100) antibodies. For intracellular cytokine analysis, cells were subsequently fixed and permeabilized using Foxp3 Staining Buffer Sets (eBioscience; 00-5253-00) and stained with anti-IFN- γ (B27; BD; 1:100), anti-TNF- α (MAb11; Biolegend; 1:20) and anti-IL-2 (MQ1-17H12; Biolegend; 1:20) antibodies. Samples were analyzed on a Fortessa X-20 (BD), and data were analyzed with FlowJo software version 10.7.1 (FlowJo LLC).

Matrix peptide pools of SARS-CoV-2 M

Matrix peptide pools included in Epitope Mapping Peptide Set SARS-CoV-2 (VME1) (JPT EMPS-WCPV-VME-1) were used to analyze M epitopes recognized by T cells.

182 PBMCs ($0.5-1.5 \times 10^5$) were stimulated with 1 $\mu\text{g/mL}$ of each M matrix peptide pool (15
183 pools of 6-8 peptides) for 18 h and subjected to IFN- γ ELISpot assays.

184

185 **Statistical analysis**

186 Unpaired t tests or Mann-Whitney U tests were performed using GraphPad Prism 9.1.0
187 software. Statistical details are provided in figure legends.

188

189

190

191

192

193

194

195

196

197

198

199

200

201 **Results**

202 **Age-related differences in SARS-CoV-2-specific T cell responses**

203 To assess whether there are age-related differences in SARS-CoV-2-specific T cell
 204 responses, we collected peripheral blood from young (20 to 50 years of age) and elderly
 205 (>70 years of age) donors in Okinawa between October 2020 and April 2021. These
 206 included 18 young and 10 elderly donors who had recovered from mild COVID-19 1-3
 207 months prior to blood collection. Antibody tests using freshly purified sera showed that
 208 93% of donors with previously diagnosed COVID-19 and 4% of those without, were
 209 seropositive for SARS-CoV-2 Spike (S). Then we divided donors into 4 groups: young
 210 seronegative (n=45), elderly seronegative (n=41), young seropositive (n=19), and elderly
 211 seropositive (n=11).

212 To compare SARS-CoV-2-specific T cell responses between age groups we
 213 performed Interferon- γ (IFN- γ) ELISpot assays using freshly purified peripheral blood
 214 mononuclear cells (PBMCs) stimulated with each of 4 peptide pools covering the major
 215 viral structural proteins [N-terminal S (S1), C-terminal S (S2), Membrane (M), or
 216 Nucleoprotein (N)]. First, we analyzed the sum of spots formed by IFN- γ -expressing cells
 217 reactive to S1, S2, N, or M antigens (hereafter referred to as spots of SNM-reactive T

cells), indicating the magnitude of SARS-CoV-2-specific T cell responses in each donor. Almost all seropositive donors exhibited strong T cell responses to SARS-CoV-2 antigens regardless of age; the frequency of SNM-reactive spots was >40 per 10⁶ PBMCs in 92% of seropositive donors. The frequency of SNM-reactive T cells in seronegative donors was more variable than in seropositive donors, but a substantial proportion of seronegative donors exhibit T cell responses comparable to those of seropositive donors (53% of young donors and 42% of elderly donors had >40 spots per 10⁶ PBMCs). In both seronegative and seropositive populations, there were no significant differences in the frequency of SNM-reactive T cells between young (seronegative; median:53, IQR:21-96, seropositive; median:312, IQR:75-1509) and elderly (seronegative; median:32, IQR:7-331, seropositive; median:778, IQR:351-2392) (Fig. 1A, 1B).

Next, we compared frequencies of T cells reactive to individual viral antigens between young and elderly donors. Among seronegative donors, the frequencies of S-2- and N-reactive T cells were significantly lower in elderly than in young persons (Fig. 1B). However, there were no significant differences in the frequencies of S-1- and M-reactive T cells between seronegative young and elderly donors (Fig. 1B). Consistent with previous reports (12), T cell responses to S-2 were higher than S-1 in the seronegative population (Fig. 1B). Frequencies of T cells specific to S1, S2, N, and M were comparable

between seropositive young and elderly donors (Fig. 1B).

We also analyzed intraindividual immunodominance of each SARS-CoV-2 antigen in donors who had >40 spots per 10⁶ PBMCs. Remarkably, M-specific responses were dominant in 6/23 young and 12/14 elderly seronegative donors (Fig. 2A). In contrast, T cell responses specific to S-1 and S-2 were more prominent than M in seropositive donors (Fig. 2B). Taken together, these data suggest that although SARS-CoV-2 infection can induce comparable T cell responses to various viral antigens in young and elderly individuals, pre-existing memory T responses specific to SARS-CoV-2 S and N antigens decrease in elderly people, while M-specific T cell responses are maintained.

Phenotypes of M-reactive T cells

Given that a proportion of seronegative donors exhibited M-specific responses comparable to those of seropositive donors, we compared phenotypes of M-reactive T cells by flow cytometry analysis. We analyzed 5 seronegative (1 young and 4 elderly) and 5 seropositive (2 young and 3 elderly) donors who had high responses to the M peptide pool (M responders). We stimulated PBMCs with the M peptide pool and stained cells with anti-CD4 or anti-CD8 antibodies, followed by intracellular cytokine staining with anti-IFN- γ antibody. Upon stimulation with the M peptide pool, CD4 T cells but not CD8

T cells significantly increased expression of IFN- γ in both seronegative and seropositive M responders and at comparable levels (Fig. 3A, 3B).

We next analyzed CD45RA and CCR7 expression to determine proportions of naïve and memory cells among M-reactive CD4 T cells. Although there was significant variation between individuals in proportions of M-reactive CD4 T cells exhibiting naïve (CD45RA⁻ CCR7⁺), effector memory (CD45RA⁺ CCR7⁻), and central memory (CD45RA⁺ CCR7⁺) phenotypes, all M responders had M-reactive memory T cells (Fig. 3C). There was no obvious difference in the proportion of naïve, effector memory, and central memory CD4 T cells between seronegative and seropositive M responders (Fig. 3C).

We also analyzed frequencies of cells expressing IL-2 and TNF- α among M-reactive CD4 T cells. Although several donors showed increased IL-2 and TNF- α expression upon stimulation with M in both seronegative and seropositive M responders, in seropositive donors, only IL-2 reached statistical significance (Fig. 3D). Seronegative and seropositive M-responders showed no detectable difference in IL-2 and TNF- α expression in T cells stimulated with M (Fig. 3D). Expression of TNF- α and IL-2 in IFN- γ -expressing CD4 T cells was comparable between seronegative and seropositive M responders (Fig. 3E). These data indicate that M-reactive T cell responses are mediated

by CD4 T cells expressing IFN- γ in both seronegative and seropositive M responders, suggesting that pre-existing M-reactive T cells and SARS-CoV-2-induced memory M-specific T cells might serve similar functions in SARS-CoV-2 infection.

Epitopes of SARS-CoV-2 M protein

To compare epitopes recognized by M-reactive T cells of seronegative and seropositive donors, we stimulated PBMCs isolated from M responders with SARS-CoV-2 M matrix pools (15 pools of 6-8 peptides) where each of 56 M-derived peptides (15-mers) is allocated to 2 different pools. In seropositive M responders, stimulation with pools 5 and 13 induced high levels of IFN- γ responses (Fig. 4A). These matrix pools shared a single peptide, M₁₄₅₋₁₆₀, suggesting that the M₁₄₅₋₁₆₀, which was previously identified as an immunodominant viral epitope in COVID-19 convalescent patents (18), is the epitope recognized by T cells of seropositive M responders. In contrast, in seronegative M responders, stimulation of PBMCs with many M matrix pools induced comparable IFN- γ responses (Fig. 4B), suggesting that various M epitopes are recognized by pre-existing T cells.

290

291 **Discussion**

292 Our data indicate that a fraction of elderly donors possess significantly high
293 levels of pre-existing SARS-CoV-2 M-specific T cell responses, though the frequency of
294 pre-existing SARS-CoV-2 S- and N-specific T cells in this population is lower. Other
295 recent studies have also reported an age-related decline of S-specific pre-existing T cells
296 (Refs. 19 and L. Loyal et al., manuscript posted on medRxiv DOI:
297 10.1101/2021.04.01.21252379). These data suggest that pre-existing T cells specific to
298 SARS-CoV-2 are heterogeneously affected by age in a target antigen-dependent manner.
299 There was no obvious difference in the sum of IFN- γ -expressing cells specific to S, N,
300 and M antigens, suggesting that abundant M-specific T cells can compensate for the loss
301 of S- and N-specific T cells, at least in the magnitude of T cell-mediated IFN- γ production,
302 in elderly individuals. Taken together, these data suggest that the diversity of target
303 antigen repertoire for pre-existing T cells may decline with age, but the magnitude of pre-
304 existing T cell responses can be maintained with T cells specific to certain viral proteins
305 such as M.

306 As the frequency of pre-existing T cells specific to viral structural proteins S, N,
307 and M is associated with protection from SARS-CoV-2 infection (D. Wyllie et al.,

manuscript posted on medRxiv DOI: 10.1101/2020.11.02.20222778) , focused M responses might be particularly important for protection of elderly individuals who have lower responses to S and N. Flow cytometry analyses revealed that CD4 T cells mainly mediate M-specific T cell responses, and their naïve/memory phenotypes and their capacity to produce IFN- γ , IL-2, and TNF- α cytokines were comparable between seronegative and seropositive groups. The phenotypic similarity suggests that pre-existing M-reactive T cells may serve similar functions to SARS-CoV-2-induced M-specific memory T cells. We speculate that pre-existing M-specific CD4 T cells play a protective role in SARS-CoV-2 infection by promoting cellular immunity through IFN- γ production and humoral immunity by providing T cell help to S- and N-specific B cells via linked recognition.

However, we cannot exclude the possibility that pre-existing M-specific T cells are harmful for some elderly individuals. Several studies suggest that pre-existing SARS-CoV-2-specific T cells are detrimental in COVID-19 (8). In particular, the frequency of M-specific T cells in COVID-19 patients is thought to be a risk factor, as it is correlated with age and severity of disease (8), although how pre-existing M-specific T cells affect magnitude, kinetics and functions of M-specific T cell responses in COVID-19 patients remains unclear. Thus, both protective and pathogenic functions of pre-existing M-

specific T cells can be speculated. A longitudinal comparison of susceptibility and symptom severity of COVID-19 between individuals with and without high pre-existing M-specific T cell responses might provide insights into this issue.

Despite defects in pre-existing T cell responses to S and N, most elderly donors who recovered from mild COVID-19 had abundant T cells specific to S and N antigens at levels comparable to those of young donors, suggesting that elderly individuals can induce T cell responses against S and N antigens upon SARS-CoV-2 infection. However, our analysis is limited to only a few patients who had recovered from mild COVID-19. Therefore, the relationship between age-related alteration of pre-existing T cells and T cell responses during infection in patients with diverse clinical outcomes of COVID-19 should be investigated in a larger, statistically valid test population.

Whether diverse SARS-CoV-2-induced T cell clones can mediate long-lasting memory responses should be addressed in future studies. It has recently been shown that SARS-CoV-2-induced memory T cells persist at least 6 months after infection (20). Interestingly, SARS-CoV-1 infection induces long-lasting (>11 years) CD8 memory T cells specific to M₁₄₁₋₁₅₅ peptide (21). Our data show that the overlapping peptide (M₁₄₅₋₁₆₀) is immunodominant in SARS-CoV-2 infection, which is consistent with a recent study showing CD4 T cell responses to the M₁₄₅₋₁₆₀ peptide in convalescent COVID-19 patients

(18). The amino acid sequence of M₁₄₅₋₁₆₀ peptide from SARS-CoV-2 shows high homology with SARS-CoV-1 and other coronaviruses (SARS-CoV-1: 81.3%, NL63: 33.0% , OC43: 47.0%, 229E: 22.7%, HKU1: 47.0%). This short M peptide is likely a potent inducer of SARS-CoV-2 M-specific memory T cells. In contrast, pre-existing T cells likely recognize various M peptides, possibly including M₁₄₅₋₁₆₀, rather than focusing on this single M peptide, as we observed in epitope mapping analysis.

What induces pre-existing M-specific T cells? Common cold coronaviruses may induce pre-existing SARS-CoV-2-specific T cell (22, 23). Amino acid sequence homology between SARS-CoV-2 and other common cold coronaviruses is relatively high for M (NL63: 25.2% , OC43: 36.9%, 229E: 26.7%, HKU1: 32.4%), S1 (NL63: 11.0% , OC43: 15.4%, 229E: 12.8%, HKU1: 15.2%), S2 (NL63: 27.3% , OC43: 36.9%, 229E: 28.0%, HKU1: 35.3%), and N (NL63: 22.3% , OC43: 26.5%, 229E: 16.2%, HKU1: 26.5%). These coronaviruses may induce polyclonal M-specific T cells. Age-related loss of memory T cells specific to common cold coronavirus S protein (19) supports the hypothesis that pre-existing M-focused T cell responses are induced by common cold coronavirus infection in elderly people. Our data showing higher frequency of pre-existing T cells specific to S-2 than S-1 are also consistent with the fact that S-2 shows higher homology between SARS-CoV-2 and other coronaviruses. However, some young

donors, as well as elderly donors, had abundant pre-existing T cells specific to M, but not to S and N, suggesting that focused T cell responses to M are not necessarily due to age-related loss of pre-existing T cells specific for S and N antigens. Interestingly, a recent study reported that T cells specific to commensal bacteria can cross-react with SARS-CoV-2 S antigen (X. Lu et al., manuscript posted on medRxiv DOI: 10.1101/2021.03.23.436573). Similarly, there may be specific microbes that induce pre-existing M-specific T cells.

It is worth considering the potential of novel COVID-19 vaccines to induce M-specific immunity. Current vaccine strategies are to induce S-specific antibody and T cell responses (24, 25). Recent studies reported a correlation between the frequency of pre-existing S-specific T cells and vaccine-induced S-specific T cell responses (L. Loyal et al., manuscript posted on medRxiv DOI: 10.1101/2021.04.01.21252379), which suggests a role of pre-existing S-specific T cells in cognate T cell help. However, elderly individuals likely would not benefit fully from pre-existing S-specific T cells. To enhance vaccine efficacy among the elderly, it might be reasonable to consider a strategy to induce not only S-specific, but also M-specific immunity, using vaccines based on inactivated viruses or M-fused S antigens. Linked recognition of M-specific T helper cells by S-specific B cells can promote S-specific antibody production by overcoming the defect of

380 cognate T cell help in elderly individuals. Further characterization of M-specific T cells
381 in young and elderly may provide new insights into vaccine-induced immunity that is less
382 affected by age.

383

384 **Acknowledgements**

385 We thank physicians and nurses at KIN oncology Clinic for excellent support to collect
386 blood samples from donors. We also thank Steven Aird for editing manuscript. We are
387 also grateful to OIST Graduate University for its generous funding of the Immune Signal
388 Unit.

References

1. Merad, M., and J. C. Martin. 2020. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nature Reviews Immunology* 20: 355-362.
2. O'Driscoll, M., G. Ribeiro Dos Santos, L. Wang, D. A. T. Cummings, A. S. Azman, J. Paireau, A. Fontanet, S. Cauchemez, and H. Salje. 2021. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* 590: 140-145.
3. Takahashi, T., M. K. Ellingson, P. Wong, B. Israelow, C. Lucas, J. Klein, J. Silva, T. Mao, J. E. Oh, M. Tokuyama, P. Lu, A. Venkataraman, A. Park, F. Liu, A. Meir, J. Sun, E. Y. Wang, A. Casanovas-Massana, A. L. Wyllie, C. B. F. Vogels, R. Earnest, S. Lapidus, I. M. Ott, A. J. Moore, A. Shaw, J. B. Fournier, C. D. Odio, S. Farhadian, C. Dela Cruz, N. D. Grubaugh, W. L. Schulz, A. M. Ring, A. I. Ko, S. B. Omer, and A. Iwasaki. 2020. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature* 588: 315-320.
4. Stefan, N., A. L. Birkenfeld, and M. B. Schulze. 2021. Global pandemics interconnected — obesity, impaired metabolic health and COVID-19.

- 407 *Nature Reviews Endocrinology* 17: 135-149.
- 408 5. Krammer, F. 2020. SARS-CoV-2 vaccines in development. *Nature* 586:
409 516-527.
- 410 6. Fajgenbaum, D. C., and C. H. June. 2020. Cytokine Storm. *New England*
411 *Journal of Medicine* 383: 2255-2273.
- 412 7. De Candia, P., F. Prattichizzo, S. Garavelli, and G. Matarese. 2021. T Cells:
413 Warriors of SARS-CoV-2 Infection. *Trends in Immunology* 42: 18-30.
- 414 8. Sattler, A., S. Angermair, H. Stockmann, K. M. Heim, D. Khadzhynov, S.
415 Treskatsch, F. Halleck, M. E. Kreis, and K. Kotsch. 2020. SARS-CoV-2–
416 specific T cell responses and correlations with COVID-19 patient
417 predisposition. *Journal of Clinical Investigation* 130: 6477-6489.
- 418 9. Rydzynski Moderbacher, C., S. I. Ramirez, J. M. Dan, A. Grifoni, K. M.
419 Hastie, D. Weiskopf, S. Belanger, R. K. Abbott, C. Kim, J. Choi, Y. Kato, E.
420 G. Crotty, C. Kim, S. A. Rawlings, J. Mateus, L. P. V. Tse, A. Frazier, R.
421 Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire, D. M. Smith, A. Sette,
422 and S. Crotty. 2020. Antigen-Specific Adaptive Immunity to SARS-CoV-2
423 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*
424 183: 996-1012.e1019.

- 425 10. Chen, G., D. Wu, W. Guo, Y. Cao, D. Huang, H. Wang, T. Wang, X. Zhang,
426 H. Chen, H. Yu, X. Zhang, M. Zhang, S. Wu, J. Song, T. Chen, M. Han, S.
427 Li, X. Luo, J. Zhao, and Q. Ning. 2020. Clinical and immunological features
428 of severe and moderate coronavirus disease 2019. *Journal of Clinical*
429 *Investigation* 130: 2620-2629.
- 430 11. Le Bert, N., H. E. Clapham, A. T. Tan, W. N. Chia, C. Y. L. Tham, J. M.
431 Lim, K. Kunasegaran, L. W. L. Tan, C.-A. Dutertre, N. Shankar, J. M. E.
432 Lim, L. J. Sun, M. Zahari, Z. M. Tun, V. Kumar, B. L. Lim, S. H. Lim, A.
433 Chia, Y.-J. Tan, P. A. Tambyah, S. Kalimuddin, D. Lye, J. G. H. Low, L.-F.
434 Wang, W. Y. Wan, L. Y. Hsu, A. Bertoletti, and C. C. Tam. 2021. Highly
435 functional virus-specific cellular immune response in asymptomatic SARS-
436 CoV-2 infection. *Journal of Experimental Medicine* 218.
- 437 12. Braun, J., L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S.
438 Hippenstiel, M. Dingeldey, B. Kruse, F. Fauchere, E. Baysal, M. Mangold,
439 L. Henze, R. Lauster, M. A. Mall, K. Beyer, J. Rohmel, S. Voigt, J. Schmitz,
440 S. Miltenyi, I. Demuth, M. A. Muller, A. Hocke, M. Witzernath, N. Suttorp,
441 F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V. M. Corman, C.
442 Giesecke-Thiel, L. E. Sander, and A. Thiel. 2020. SARS-CoV-2-reactive T

443 cells in healthy donors and patients with COVID-19. *Nature* 587: 270-274.

444 13. Le Bert, N., A. T. Tan, K. Kunasegaran, C. Y. L. Tham, M. Hafezi, A. Chia,
445 M. H. Y. Chng, M. Lin, N. Tan, M. Linster, W. N. Chia, M. I. C. Chen, L.-
446 F. Wang, E. E. Ooi, S. Kalimuddin, P. A. Tambyah, J. G.-H. Low, Y.-J. Tan,
447 and A. Bertoletti. 2020. SARS-CoV-2-specific T cell immunity in cases of
448 COVID-19 and SARS, and uninfected controls. *Nature* 584: 457-462.

449 14. Woldemeskel, B. A., A. K. Kwaa, C. C. Garliss, O. Laeyendecker, S. C. Ray,
450 and J. N. Blankson. 2020. Healthy donor T cell responses to common cold
451 coronaviruses and SARS-CoV-2. *Journal of Clinical Investigation* 130:
452 6631-6638.

453 15. Bacher, P., E. Rosati, D. Esser, G. R. Martini, C. Saggau, E. Schiminsky, J.
454 Dargvainiene, I. Schroder, I. Wieters, Y. Khodamoradi, F. Eberhardt, M.
455 Vehreschild, H. Neb, M. Sonntagbauer, C. Conrad, F. Tran, P. Rosenstiel,
456 R. Markewitz, K. P. Wandinger, M. Augustin, J. Rybniker, M. Kochanek, F.
457 Leypoldt, O. A. Cornely, P. Koehler, A. Franke, and A. Scheffold. 2020.
458 Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed
459 Individuals and Humans with Severe COVID-19. *Immunity* 53: 1258-1271
460 e1255.

- 461 16. Chen, Z., and E. John Wherry. 2020. T cell responses in patients with
462 COVID-19. *Nature Reviews Immunology* 20: 529-536.
- 463 17. Sahin, U., A. Muik, E. Derhovanessian, I. Vogler, L. M. Kranz, M. Vormehr,
464 A. Baum, K. Pascal, J. Quandt, D. Maurus, S. Brachtendorf, V. Lörks, J.
465 Sikorski, R. Hilker, D. Becker, A.-K. Eller, J. Grützner, C. Boesler, C.
466 Rosenbaum, M.-C. Kühnle, U. Luxemburger, A. Kemmer-Brück, D.
467 Langer, M. Bexon, S. Bolte, K. Karikó, T. Palanche, B. Fischer, A. Schultz,
468 P.-Y. Shi, C. Fontes-Garfias, J. L. Perez, K. A. Swanson, J. Loschko, I. L.
469 Scully, M. Cutler, W. Kalina, C. A. Kyratsous, D. Cooper, P. R. Dormitzer,
470 K. U. Jansen, and Ö. Türeci. 2020. COVID-19 vaccine BNT162b1 elicits
471 human antibody and TH1 T cell responses. *Nature* 586: 594-599.
- 472 18. Keller, M. D., K. M. Harris, M. A. Jensen-Wachspress, V. V. Kankate, H.
473 Lang, C. A. Lazarski, J. Durkee-Shock, P.-H. Lee, K. Chaudhry, K. Webber,
474 A. Datar, M. Terpilowski, E. K. Reynolds, E. M. Stevenson, S. Val, Z.
475 Shancer, N. Zhang, R. Ulrey, U. Ekanem, M. Stanojevic, A. Geiger, H.
476 Liang, F. Hoq, A. A. Abraham, P. J. Hanley, C. R. Cruz, K. Ferrer, L.
477 Dropulic, K. Gangler, P. D. Burbelo, R. B. Jones, J. I. Cohen, and C. M.
478 Bollard. 2020. SARS-CoV-2-specific T cells are rapidly expanded for

- therapeutic use and target conserved regions of the membrane protein.
- Blood* 136: 2905-2917.
19. Saletti, G., T. Gerlach, J. M. Jansen, A. Molle, H. Elbahesh, M. Ludlow, W. Li, B.-J. Bosch, A. D. M. E. Osterhaus, and G. F. Rimmelzwaan. 2020. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. *Scientific Reports* 10.
20. Jiang, X.-L., G.-L. Wang, X.-N. Zhao, F.-H. Yan, L. Yao, Z.-Q. Kou, S.-X. Ji, X.-L. Zhang, C.-B. Li, L.-J. Duan, Y. Li, Y.-W. Zhang, Q. Duan, T.-C. Wang, E.-T. Li, X. Wei, Q.-Y. Wang, X.-F. Wang, W.-Y. Sun, Y.-W. Gao, D.-M. Kang, J.-Y. Zhang, and M.-J. Ma. 2021. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. *Nature Communications* 12.
21. Ng, O.-W., A. Chia, A. T. Tan, R. S. Jadi, H. N. Leong, A. Bertoletti, and Y.-J. Tan. 2016. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. *Vaccine* 34: 2008-2014.
22. Sagar, M., K. Reifler, M. Rossi, N. S. Miller, P. Sinha, L. F. White, and J. P. Mizgerd. 2021. Recent endemic coronavirus infection is associated with less-severe COVID-19. *Journal of Clinical Investigation* 131.

- 497 23. Mateus, J., A. Grifoni, A. Tarke, J. Sidney, S. I. Ramirez, J. M. Dan, Z. C.
498 Burger, S. A. Rawlings, D. M. Smith, E. Phillips, S. Mallal, M. Lammers, P.
499 Rubiro, L. Quiambao, A. Sutherland, E. D. Yu, R. Da Silva Antunes, J.
500 Greenbaum, A. Frazier, A. J. Markmann, L. Premkumar, A. De Silva, B.
501 Peters, S. Crotty, A. Sette, and D. Weiskopf. 2020. Selective and cross-
502 reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* 370:
503 89-94.
- 504 24. Corbett, K. S., D. K. Edwards, S. R. Leist, O. M. Abiona, S. Boyoglu-
505 Barnum, R. A. Gillespie, S. Himansu, A. Schäfer, C. T. Ziwawo, A. T.
506 Dipiazza, K. H. Dinnon, S. M. Elbashir, C. A. Shaw, A. Woods, E. J. Fritch,
507 D. R. Martinez, K. W. Bock, M. Minai, B. M. Nagata, G. B. Hutchinson, K.
508 Wu, C. Henry, K. Bahl, D. Garcia-Dominguez, L. Ma, I. Renzi, W.-P. Kong,
509 S. D. Schmidt, L. Wang, Y. Zhang, E. Phung, L. A. Chang, R. J. Loomis, N.
510 E. Altaras, E. Narayanan, M. Metkar, V. Presnyak, C. Liu, M. K. Louder,
511 W. Shi, K. Leung, E. S. Yang, A. West, K. L. Gully, L. J. Stevens, N. Wang,
512 D. Wrapp, N. A. Doria-Rose, G. Stewart-Jones, H. Bennett, G. S. Alvarado,
513 M. C. Nason, T. J. Ruckwardt, J. S. McLellan, M. R. Denison, J. D. Chappell,
514 I. N. Moore, K. M. Morabito, J. R. Mascola, R. S. Baric, A. Carfi, and B. S.

515 Graham. 2020. SARS-CoV-2 mRNA vaccine design enabled by prototype
516 pathogen preparedness. *Nature* 586: 567-571.

517 25. Polack, F. P., S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart,
518 J. L. Perez, G. Pérez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A.
519 Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R.
520 W. Frenck, L. L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, D. B.
521 Tresnan, S. Mather, P. R. Dormitzer, U. Şahin, K. U. Jansen, and W. C.
522 Gruber. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19
523 Vaccine. *New England Journal of Medicine* 383: 2603-2615.

524

Figure Legends

Fig. 1. Altered pre-existing T cell responses to SARS-CoV-2 structural proteins in elderly donors.

PBMCs isolated from seronegative (**A**) and seropositive (**B**) young (20-50 years of age) and elderly (>70 years of age) donors were stimulated with peptide pools for SARS-CoV-2 S, N, and M proteins and subjected to IFN- γ ELISpot analysis. Spot-forming units representing the frequency of IFN- γ -secreting cells in seronegative young (n=45), seronegative elderly (n=41), seropositive young (n=19), and seropositive elderly (n=11) are shown. The sum of spots formed by cells stimulated with S, N, and M (SNM) is also shown. Statistical comparisons between age groups utilized the Mann-Whitney test. *P<0.05, ns: not significant.

Fig. 2. M-specific pre-existing T cell responses predominate in elderly donors.

Ratios of spots formed by cells stimulated with SARS-CoV-2 S, N, and M peptide pools in ELISpot data (in Fig. 1.) were analyzed in seronegative (**A**) and seropositive (**B**) donors who had >40 spots/10⁶ PBMCs in the sum of spots formed by cells stimulated with S, N, and M.

Fig. 3. Pre-existing and SARS-CoV-2-induced M-specific T cells exhibit similar phenotypes.

PBMCs isolated from seronegative (n=5) and seropositive (n=5) M responders were stimulated with an M peptide pool for 7 hours and analyzed by flow cytometry. The flow cytometry gating strategy was shown in Supplemental Figure 1. (A) Dot plots represent IFN- γ expression in CD4 and CD8 T cells of subject #31 (seronegative, >70 years of age). (B) Percentages of IFN- γ -expressing cells among CD4 and CD8 T cells were analyzed. (C) Percentages of naïve (T_n), central memory (T_{cm}), and effector memory (T_{em}) among IFN- γ -expressing cells stimulated with M. (D, E) Percentages of TNF- α - and IL-2-expressing cells among total CD4 T cells (D) and IFN- γ -expressing CD4 T cells (E) stimulated with M. (B-E) Data shown as mean $\pm$ SD. Each dot represents an individual donor. Blue and orange dots indicate results of young and elderly donors, respectively. Statistical analysis utilized unpaired two-tailed Student's t tests. *P<0.05, ns: not significant.

Fig. 4. SARS-CoV-2 M epitopes recognized by T cells.

PBMCs isolated from M responders in seropositive (A) and seronegative (B) groups were stimulated with SARS-CoV-2 M matrix pools (15 pools) for 16 h and subjected to IFN- γ

561 ELISpot analysis. Spot-forming units representing the frequency of IFN- γ -secreting cells.

562 Blue and orange bars indicate results of young and elderly donors, respectively.

563

Figure 1

Figure 3

medRxiv preprint doi: <https://doi.org/10.1101/2021.07.26.21261082>; this version posted July 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 4

A

B